SBIR/STTR Research Award

Bactericidal agents for slow-growing bacteria

Award identifier af57888aa029016c2eae79d7a24dc90488742ecfe0593ab765966aafea0a78b7Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$126,280

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
INFLUX, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): In many chronic infections, including all biofilm related infections, the slow growth of bacteria is believed to account not only for resistance to antibiotics, but also for the high incidence of persistence and relapse. Considering that all currently prescribed antibiotics are significantly more effective against rapidly growing pathogens, the development of antibiotics highly effective against bacteria in the slow mode of growth is of utmost importance. By screening a chemical library for compounds bactericidal for slow-growing S. aureus, we have succeeded in identifying a very promising class of compounds, pyridinium thiol ethers (PTEs). Preliminary data indicate that PTEs are not only effective against fluid-phase S. aureus, but also against biofilms as well as against other bacteria in a slow mode of growth. In the proposed Phase I project, we will synthesize and screen a library of PTEs in order to identify compounds that will be bactericidal against slow and logarithmically growing S. aureus. Feasibility of the medical use of the most active derivatives will be analyzed. Finally, the basic principles underlying the molecular mechanism of action of PTE compounds will be investigated. The Phase I project will provide the basis for the Phase II project, which will involve chemical improvement of the lead compounds, investigation of their activity in various biofilm models, and in vivo toxicology studies. PTE compounds could provide a unique opportunity for eradication of infections associated with slow bacterial growth.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.